ARTHRIX
HIKMA
Identification
- Active ingredient (INN)
- ETORICOXIB
- Internal code
- 04 B 075
- Country of Origin
- Algeria
- Pharmaceutical form
- Scored Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/30
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Etoricoxib is a new
COX-2 selective inhibitor.
Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Like any other
COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid.
It is approved in more than 60 countries worldwide but not in the US.
Indications
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Pharmacodynamics
Etoricoxib is a
COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).
Absorption
Bioavailability is 100% following oral administration.
Metabolism
Hepatic, primarily via CYP3A4.
Hover over products below to view reaction partners Etoricoxib Etoricoxib 1'-N'-oxide 6-Hydroxymethyletoricoxib 6-Hydroxymethyletoricoxib glucuronide 6-Carboxy-etoricoxib 6-Hydroxymethyletoricoxib 1'-N'-oxide.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB.
Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo.